US FDA panel votes to keep controversial asthma indications for two drugs
This article was originally published in SRA
US Food and Drug Administration advisory committee members have recommended that long-acting beta-2 adrenergic agonist (LABA) combination products should continue to be used for asthma, but the single-agent LABAs salmeterol and formoterol should be stripped of their current indications because of increased risks of asthma-related death and exacerbations with monotherapy1.
You may also be interested in...
The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.
US FDA will survey health care providers’ current understanding of analgesic abuse-deterrent formulations and conduct an experimental study exploring the effectiveness of different terminology and descriptions for such products; agency has heard complaints from its own AdComms about terminology around abuse deterrence.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.